Author:
Liang Wenhua,He Qihua,Chen Ying,Chuai Shaokun,Yin Weiqiang,Wang Wei,Peng Guilin,Zhou Caicun,He Jianxing
Funder
Guangdong Doctoral Launching Program
Doctoral Launching Program of Guangzhou Medical University
Guangzhou Health and Medical Collaborative Innovative Major Special Projects
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference16 articles.
1. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105(9):595–605.
2. Qian H, Gao F, Wang H, Ma F. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lungcancer: a meta-analysis of clinical trials. BMC Cancer. 2014;14:683.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM. Non-Small Cell Lung Cancer. V5.2015. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf . Accessed March; 2015.
4. Gray J, Haura E. Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res. 2014;3(6):360–2.
5. Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, et al. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8(1):17.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献